In order to thrive, you need to have all of the tools at your fingertips, and that includes evidence-based therapies that go beyond conventional oncology.
Download our FREE PDF guide filled with evidence-based therapies that you can start today to manage your Pancreatic Cancer. Click the orange button to get your download now.
I have nothing against conventional oncology. Really I don’t. Unfortunately, conventional oncology has little to offer pancreatic cancer patients.
Consider complementary therapies. Consider integrative therapies,
I am telling you to look past conventional therapies for your incurable cancer only because my cancer is also incurable. And I spent several years undergoing conventional chemotherapy, radiation and an autologous stem cell transplant. Only to be told that there was nothing more that my oncologist could do for me.
That’s what the “thunder god vine” looks like.
For the record, there are evidence-based “integrative therapies.” Curcumin, for example, has been shown to enhance the efficacy of conventional chemotherapy such as gemcitabine.
I am a cancer survivor and cancer coach. Have you been diagnosed with pancreatic cancer? If so, what stage? What therapies are you considering? Please scroll down the page, post a question or comment and I will reply to you ASAP.
Thanks and hang in there,
“Triptolide is a diterpenoid epoxide which is endogenously produced by the thunder god vine, Tripterygium wilfordii. It has in vitroand in vivo activities against mouse models of polycystic kidney disease and pancreatic cancer, but its physical properties limit its therapeutic potential. Consequently, a synthetic prodrug, minnelide, is being studied clinically instead. Due to its low solubility in water, several water-soluble analogs have been formulated, including Minnelide, which is currently in Phase I clinical trials.“
“Standard of Care in pancreatic cancer- Over the past several decades, PDAC survival rates have not improved due in large part to delayed detection, metastasis , and drug resistance of PDAC cells . This underscores the importance of effective, targeted chemotherapies to treat pancreatic cancer as it grows aggressively, is highly metastatic and yet remains resistant to chemotherapy. There are currently three main FDA-approved therapies. 5-fluorouracil, a pyrimidine analog, has been used since the 1970s. Gemcitabine, a nucleoside analog, was approved in 1996 and provides a 1.5-month survival advantage over 5-fluorouracil. Erlotinib, approved in 2006, adds a mere 10 days to the survival rate achieved by gemcitabine . Erlotinib inhibits the tyrosine kinase epidermal growth factor receptor (EGFR), and its administration has shown modest benefit in clinical trials [13–15]. As of September 2013, Abraxene, an albumin binding form of paclitaxel, has been approved by FDA for pancreatic cancer, as it showed a survival advantage of 5 months when used in combination with Gemcitabine. In spite of this, the need for more effective chemotherapeutic agents conferring better survival advantages is needed in this disease.
“The herbal extract triptolide has been used on human pancreatic cancer cells and tissue in culture by researchers. Administration of the herb decreased GRP78 protein in the cells, thereby reducing cancer cell survival and facilitating cell death…
Our study shows that although increased expression of GRP78 confers a survival advantage to the tumor cells, prolonged exposure to triptolide induces chronic ER stress, which eventually leads to cell death,” the authors stated. “In this context, inhibition of GRP78 by activation of the ER stress pathway by triptolide offers a novel mechanism for inhibiting the growth and survival of pancreatic cancer cells.”
“A number of preclinical studies have demonstrated anticancer effects for curcumin in various types of tumors, including pancreatic cancer. Curcumin has anticancer effects both alone and in combination with other anticancer drugs (e.g., gemcitabine, 5-fluorouracil, and oxaliplatin), and it has been shown to modulate a variety of molecular targets in preclinical models, with more than 30 molecular targets identified to date.
Of these various molecules, NF-κB is thought to be one of the primary targets of curcumin activity. Based on these promising preclinical results, several research groups, including our own, have progressed to testing the anticancer effects of curcumin in clinical trials; however, the poor bioavailability of this agent has been the major challenge for its clinical application.
Despite the ingestion of gram-level doses of curcumin, plasma curcumin levels remain at low (ng/mL) levels in patients, which is insufficient to yield the anticancer benefits of curcumin. This problem has been solved by the development of highly bioavailable forms of curcumin (THERACURMIN®), and higher plasma curcumin levels can now be achieved without increased toxicity in patients with pancreatic cancer. In this article, we review possible therapeutic applications of curcumin in patients with pancreatic cancer…
A growing body of evidence supports the idea that curcumin is a promising anticancer drug. In preclinical models, curcumin has been shown to have anticancer effects, both alone and in combination with other anticancer drugs, through the modulation of a variety of molecular targets.
However, the poor bioavailability of curcumin has been the major challenge to its clinical application. This problem has now been solved by the development of highly bioavailable forms of curcumin (THERACURMIN®), which can induce higher plasma curcumin levels without increased toxicity. Further clinical trials will be necessary to test the therapeutic applications of this promising agent in patients with pancreatic cancer.”